Safety of cotinine in humans: Physiologic, subjective, and cognitive effects

被引:62
作者
Hatsukami, DK
Grillo, M
Pentel, PR
Oncken, C
Bliss, R
机构
[1] HENNEPIN CTY MED CTR, DEPT MED, MINNEAPOLIS, MN 55415 USA
[2] UNIV CONNECTICUT, VET ADM MED CTR, NEWINGTON, CT 06111 USA
关键词
cotinine; subjective effects; physiologic effects; cognitive effects; withdrawal; significance;
D O I
10.1016/S0091-3057(97)80001-9
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Preliminary data suggest that cotinine, the major metabolite of nicotine, may be behaviorally active. Studies involving the administration of cotinine at doses that produce high blood concentrations (in excess of those produced by cigarette smoking) may be of interest. This inpatient, 10-day human study examined the safety and the effects from several high doses of oral cotinine fumarate (40, 80, or 160 mg) or placebo in abstinent cigarette smokers. All subjects smoked cigarettes ad lib during the first 2 days of the study, then were required to be abstinent beginning on the third day. All subjects were given placebo on this day to wash out nicotine before the administration of cotinine. Subjects were subsequently randomly assigned in a double blind manner to cotinine or placebo for the next 3 days to determine the safety profile of cotinine. All subjects were given placebo on the final 3 days to examine cotinine withdrawal symptoms. The results showed no significant physiologic, subjective, or performance effects across the various doses of cotinine and placebo. Furthermore, no cotinine withdrawal effects were observed. This study demonstrates that short-term administration of cotinine to humans at levels as high as 10 times that attained from cigarette smoking is safe with no observable acute or withdrawal effects from cotinine in this setting. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:643 / 650
页数:8
相关论文
共 31 条
[1]   POSSIBLE RELATION BETWEEN PKA1 AND LIPID SOLUBILITY AND AMOUNTS EXCRETED IN URINE OF SOME TOBACCO ALKALOIDS GIVEN TO MAN [J].
BECKETT, AH ;
JENNER, P ;
GORROD, JW .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1972, 24 (02) :115-&
[2]   INVERSE RELATION BETWEEN SERUM COTININE CONCENTRATION AND BLOOD-PRESSURE IN CIGARETTE SMOKERS [J].
BENOWITZ, NL ;
SHARP, DS .
CIRCULATION, 1989, 80 (05) :1309-1312
[3]   COTININE DISPOSITION AND EFFECTS [J].
BENOWITZ, NL ;
KUYT, F ;
JACOB, P ;
JONES, RT ;
OSMAN, AL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 34 (05) :604-611
[4]  
BORZELLECA JF, 1962, J PHARMACOL EXP THER, V137, P313
[5]  
BOWMAN ER, 1962, J PHARMACOL EXP THER, V135, P306
[6]  
BOWMAN ER, 1963, BIOCHEM PREP, V10, P36
[7]   NICOTINE DEPENDENCE IN RATS [J].
CARROLL, ME ;
LAC, ST ;
ASENCIO, M ;
KEENAN, RM .
LIFE SCIENCES, 1989, 45 (15) :1381-1388
[8]  
CARSKADON MA, 1976, AM J PSYCHIAT, V133, P1382
[9]   THE PHARMACOKINETICS OF COTININE IN PLASMA AND SALIVA FROM NONSMOKING HEALTHY-VOLUNTEERS [J].
CURVALL, M ;
ELWIN, CE ;
KAZEMIVALA, E ;
WARHOLM, C ;
ENZELL, CR .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 38 (03) :281-287
[10]   KINETICS OF COTININE AFTER ORAL AND INTRAVENOUS ADMINISTRATION TO MAN [J].
DESCHEPPER, PJ ;
VANHECKEN, A ;
DAENENS, P ;
VANROSSUM, JM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 31 (05) :583-588